Athira Pharma, Inc.

NasdaqGS:ATHA Stock Report

Market Cap: US$95.8m

Athira Pharma Management

Management criteria checks 0/4

Athira Pharma's CEO ist Mark Litton , ernannt in Oct 2021, hat eine Amtszeit von 2.17 Jahren. Die jährliche Gesamtvergütung beträgt $3.78M , bestehend aus 14.4% Gehalt und 85.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.39% der Aktien des Unternehmens, im Wert von $305.26K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.5 Jahre bzw. 2 Jahre.

Key information

Mark Litton

Chief executive officer

US$3.8m

Total compensation

CEO salary percentage14.4%
CEO tenure2.5yrs
CEO ownership0.05%
Management average tenure1.9yrs
Board average tenure2.4yrs

Recent management updates

Recent updates

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Feb 16
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Nov 02
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

May 29
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Jan 04
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Oct 17

Athira Pharma GAAP EPS of -$0.65

Aug 15

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Aug 09
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Jun 22

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

May 08
Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Jan 11
We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Athira Pharma: What, Exactly, Did The CEO Do?

Jun 29

Athira Pharma falls after the decision to place CEO on temporary leave

Jun 17

Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy

Jun 07

We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

May 24
We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Feb 08
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach

Jan 11

Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Dec 18
Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Athira Pharma nabs research grant of $15M from NIH

Dec 08

Athira Pharma reports Q3 results

Nov 12

CEO Compensation Analysis

How has Mark Litton's remuneration changed compared to Athira Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$118m

Sep 30 2023n/an/a

-US$121m

Jun 30 2023n/an/a

-US$108m

Mar 31 2023n/an/a

-US$102m

Dec 31 2022US$4mUS$543k

-US$96m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$77m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$3mUS$450k

-US$55m

Sep 30 2021n/an/a

-US$46m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$27m

Dec 31 2020n/an/a

-US$20m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$6m

Mar 31 2020n/an/a

-US$6m

Dec 31 2019US$204kUS$12k

-US$5m

Vergütung im Vergleich zum Markt: MarkDie Gesamtvergütung ($USD3.78M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD738.70K).

Entschädigung vs. Einkommen: MarkDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.


CEO

Mark Litton (55 yo)

2.5yrs

Tenure

US$3,775,199

Compensation

Dr. Mark J. Litton, Ph D., MBA, serves as Director at Lumen Bioscience, Inc. since October 2020. He served as Chief Operating Officer of Athira Pharma, Inc. since July 2019 until October 18, 2021 and serve...


Leadership Team

NamePositionTenureCompensationOwnership
Mark Litton
President2.5yrsUS$3.78m0.051%
$ 49.2k
Rachel Lenington
Chief Development Officer & COO2.5yrsUS$2.03m0.035%
$ 33.5k
Andrew Gengos
CFO & Chief Business Officerless than a yearno data0.22%
$ 209.5k
Kevin Church
Chief Scientific Officer1.3yrsUS$135.32k0.21%
$ 200.6k
Julie Rathbun
Head of Investor Relationsno datano datano data
Mark Worthington
General Counsel & Corporate Secretary2.8yrsUS$2.71m0.090%
$ 86.1k
Samantha Willing
Chief People Officerless than a yearno datano data

1.9yrs

Average Tenure

55yo

Average Age

Erfahrenes Management: ATHADas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.5 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.


Board Members

NamePositionTenureCompensationOwnership
Mark Litton
President2.5yrsUS$3.78m0.051%
$ 49.2k
John Fluke
Independent Director9.3yrsUS$140.56k0.52%
$ 500.9k
Grant Pickering
Independent Director2.3yrsUS$265.96k0.067%
$ 64.5k
Kelly Romano
Independent Chairwoman of the Board3.3yrsUS$166.56k0.10%
$ 95.8k
Joseph Edelman
Independent Director3.9yrsUS$138.06k14.1%
$ 13.5m
Hans Moebius
Chairman of Scientific Advisory Board1.8yrsUS$2.10m0.24%
$ 228.7k
Marwan Sabbagh
Member of Scientific Advisory Board1.8yrsno datano data
Barbara Kosacz
Independent Director3.1yrsUS$147.06k0%
$ 0
Michael A. Panzara
Independent Director2.1yrsUS$263.54k0%
$ 0
James Johnson
Independent Director3.7yrsUS$149.06k0.013%
$ 12.5k
John Olichney
Member of Scientific Advisory Board1.8yrsno datano data
Anton Porsteinsson
Member of Scientific Advisory Board1.8yrsno datano data

2.4yrs

Average Tenure

62.5yo

Average Age

Erfahrener Vorstand: ATHADie Vorstandsmitglieder gelten nicht als erfahren ( 2 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.